Introduction of Australian post-market reviews of pharmaceutical benefits scheme subsidized medicines and its implication to China / 中国药房
China Pharmacy
; (12): 1793-1797, 2023.
Article
em Zh
| WPRIM
| ID: wpr-979925
Biblioteca responsável:
WPRO
ABSTRACT
OBJECTIVE To provide a reference for strengthening the post-admission management of drugs on the medicare formulary in China. METHODS The basic situation, implementation process and effect of post-market reviews (PMR) were introduced after marketing approval of the Australian pharmaceutical benefits scheme (PBS) subsidized medicines. The suggestions were put forward for post-admission management of medicare formulary drugs in China. RESULTS & CONCLUSIONS PMR system exemplified Australia’s concept of life-cycle management of medicines on the PBS catalogue; as a mechanism for managing the admission and adjustment of PBS medicines, it provided a continuous evaluation of medicines in the PBS catalogue; the process mainly included two types: the pre-initiation process of PBS drug review and the PBS drug review process, involving steps such as drug selection, determination of review scope, and implementation management. Through PMR, Australia had completed the review of multiple medicines in nine treatment areas including diabetes, childhood asthma and Alzheimer’s disease in the PBS catalogue. The author suggests that China can improve the post-admission review of medicines at the institutional level (clarifying the selection criteria and methods of the review object, main procedures and responsible parties, and ensuring the transparency of the review process); specify the National Healthcare Security Administration or the third-party organization until a special technical organization is established to take charge of this work; at the same time, further improve the construction of data collection and monitoring systems.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
China Pharmacy
Ano de publicação:
2023
Tipo de documento:
Article